Clene Inc. Warrant

Clene Inc. will host an investor call and webcast on December 3, 2025, to provide an update on its CNM-Au8 program for treating amyotrophic lateral sclerosis (ALS). The company is a late clinical-stage biopharmaceutical firm focused on neurodegenerative disease treatments.

Clene, a clinical-stage biopharmaceutical company, reported a net loss of $(0.78) per share in Q2 2025, with minimal revenue of $27,000. The company continues advancing its CNM-Au8 therapy for neurodegenerative diseases while managing tight cash resources.

Crude oil prices declined by 1%, while shares of Soligenix surged 282% after the company announced positive interim results for its HyBryte treatment. Helen of Troy reported soft Q1 earnings and lowered its FY25 guidance, leading to a 30% drop in its stock price.